Related content

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

By Pitako J.   Haas P.   Bosch J.   Müller-Berndorff H.   Kündgen A.   Germing U.   Wijermans P.   Lübbert M.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series

By Coutinho Rita   Costa Dolors   Carrió Ana   Muñoz Concha   Vidal Ana   Belkaid Mohammed   Campo Elias   Nomdedeu Benet  

Annals of Hematology, Vol. 89, Iss. 10, 2010-10 ,pp. : 1069-1070

Springer Publishing Company

Access to resources Recommend Favorite

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

By Wijermans P.   Lübbert M.   Verhoef G.   Klimek V.   Bosly A.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome

By Baumann I.   Scheid C.   Koref M.S.   Swindell R.   Stern P.   Testa N.G.  

Experimental Hematology, Vol. 30, Iss. 12, 2002-12 ,pp. : 1405-1411

Elsevier

Access to resources Recommend Favorite

Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island

By Yagisawa Kumiko  

International Journal of Hematology, Vol. 95, Iss. 4, 2012-04 ,pp. : 420-427

Springer Publishing Company

Access to resources Recommend Favorite